Matthew J Ellis

29PUBLICATIONS

246CO-AUTHORS

Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisCancer cell biology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (29)

Sort by Publication Date:

|Jul 15, 2026

LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.

|Jan 16, 2026

Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer.

Bree M Lege, Khushali J Patel, Brendan Panici

|Aug 27, 2025

NF1-depleted ER<sup>+</sup> breast cancers are differentially sensitive to CDK4/6 inhibitors.

Ze-Yi Zheng, Anran Chen, Eric J Jaehnig

|Aug 08, 2025

Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer.

Nicholas J Neill, Shankha Satpathy, Karsten Krug

|Jun 23, 2025

Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole.

Judith-Anne W Chapman, Jane Bayani, Sandip SenGupta

|Jan 08, 2025

Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.

John F R Robertson, Zhimin Shao, Shinzaburo Noguchi

Pageof 5

Frequent Collaborators

10 joint publications

Meenakshi Anurag

Jonathan T Lei

Bing Zhang

Beom-Jun Kim

Lacey E Dobrolecki

Xuxu Gou

Susan G Hilsenbeck

Bora Lim

Charles E Foulds

Anna Malovannaya

Frequent Collaborators

10 joint publications

Meenakshi Anurag

8 joint publications

Jonathan T Lei

7 joint publications

Bing Zhang

6 joint publications

Beom-Jun Kim